Bio-Path completes first doses cohort of Phase 1/1b trial of BP1002

Bio-Path Holdings announced completion of the first dose cohort of the dose escalation portion of its Phase 1/1b clinical trial of BP1002 evaluating the ability of BP1002 to treat refractory/relapsed acute myeloid leukemia patients including venetoclax-resistant patients. “We are delighted to safely complete this first dose cohort and to advance BP1002 into the next cohort as it brings us one step closer to providing access to this very promising treatment for the most vulnerable patients who have limited therapeutic options,” said Peter Nielsen, President and Chief Executive Officer of Bio-Path Holdings. “We look forward to advancing this study in higher doses with the hope that increased levels of BP1002 will prove even more efficacious and safe in these sickest of sick patients.”